Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Receives $700.00 Average Price Target from Brokerages

Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) have been assigned an average recommendation of “Hold” from the three analysts that are currently covering the firm, MarketBeat reports. Three analysts have rated the stock with a hold recommendation. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $700.00.

Several analysts have recently issued reports on the stock. HC Wainwright reissued a “neutral” rating on shares of Atara Biotherapeutics in a research report on Wednesday, May 22nd. StockNews.com assumed coverage on shares of Atara Biotherapeutics in a research report on Wednesday. They issued a “hold” rating on the stock.

Insider Buying and Selling

In related news, EVP Anhco Nguyen sold 1,715 shares of the company’s stock in a transaction that occurred on Thursday, May 16th. The shares were sold at an average price of $15.50, for a total transaction of $26,582.50. Following the sale, the executive vice president now owns 35,939 shares of the company’s stock, valued at approximately $557,054.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Atara Biotherapeutics news, CEO Pascal Touchon sold 3,260 shares of the business’s stock in a transaction that occurred on Thursday, May 16th. The shares were sold at an average price of $15.50, for a total value of $50,530.00. Following the completion of the transaction, the chief executive officer now owns 73,165 shares of the company’s stock, valued at approximately $1,134,057.50. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, EVP Anhco Nguyen sold 1,715 shares of the business’s stock in a transaction that occurred on Thursday, May 16th. The stock was sold at an average price of $15.50, for a total transaction of $26,582.50. Following the completion of the transaction, the executive vice president now directly owns 35,939 shares of the company’s stock, valued at approximately $557,054.50. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 6,120 shares of company stock valued at $94,860. Company insiders own 3.70% of the company’s stock.

Hedge Funds Weigh In On Atara Biotherapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of ATRA. Delap Wealth Advisory LLC purchased a new position in Atara Biotherapeutics in the 1st quarter worth approximately $29,000. Vontobel Holding Ltd. purchased a new stake in shares of Atara Biotherapeutics in the 4th quarter valued at $41,000. Harbor Capital Advisors Inc. boosted its stake in shares of Atara Biotherapeutics by 368.0% in the 4th quarter. Harbor Capital Advisors Inc. now owns 208,827 shares of the biotechnology company’s stock valued at $107,000 after purchasing an additional 164,206 shares in the last quarter. BNP Paribas Financial Markets boosted its stake in shares of Atara Biotherapeutics by 29.3% in the 1st quarter. BNP Paribas Financial Markets now owns 383,082 shares of the biotechnology company’s stock valued at $266,000 after purchasing an additional 86,842 shares in the last quarter. Finally, Josh Arnold Investment Consultant LLC boosted its stake in shares of Atara Biotherapeutics by 17.6% in the 3rd quarter. Josh Arnold Investment Consultant LLC now owns 200,000 shares of the biotechnology company’s stock valued at $300,000 after purchasing an additional 30,000 shares in the last quarter. Hedge funds and other institutional investors own 70.90% of the company’s stock.

Atara Biotherapeutics Stock Performance

Shares of ATRA stock opened at $8.26 on Friday. The firm has a market cap of $39.81 million, a price-to-earnings ratio of -0.16 and a beta of 0.54. Atara Biotherapeutics has a 52 week low of $4.96 and a 52 week high of $63.38. The firm’s 50-day simple moving average is $14.22 and its two-hundred day simple moving average is $16.19.

Atara Biotherapeutics (NASDAQ:ATRA) last posted its quarterly earnings results on Thursday, May 9th. The biotechnology company reported ($5.75) earnings per share (EPS) for the quarter, beating the consensus estimate of ($9.25) by $3.50. Atara Biotherapeutics had a negative net margin of 671.70% and a negative return on equity of 783.31%. The company had revenue of $27.36 million for the quarter, compared to analyst estimates of $27.00 million. Analysts forecast that Atara Biotherapeutics will post -15.75 earnings per share for the current year.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.